Extensive impact of non-antibiotic drugs on human gut bacteria

Nature

Volumn 555, Issue 7698, 2018, Pages 623-628

  Maier, Lisa ^a   Pruteanu, Mihaela ^a,f   Kuhn, Michael ^a   Zeller, Georg ^a   Telzerow, Anja ^a   Anderson, Exene Erin ^a   Brochado, Ana Rita ^a   Fernandez, Keith Conrad ^a   Dose, Hitomi ^b   Mori, Hirotada ^b   Patil, Kiran Raosaheb ^a   Bork, Peer ^a,c,d,e   Typas, Athanasios ^a  

^a EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^b NARA INSTITUTE OF SCIENCE AND TECHNOLOGY   (Japan)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d Molecular Medicine Partnership Unit   (Germany)

^e UNIVERSITY OF WÜRZBURG   (Germany)

^f HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; NEUROLEPTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTICS; BACTERIUM; COHORT ANALYSIS; COMMUNITY STRUCTURE; DIGESTIVE SYSTEM; LABORATORY METHOD; MICROBIAL COMMUNITY;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; CORRELATIONAL STUDY; DRUG DESIGN; DRUG MARKETING; DRUG MECHANISM; DRUG POTENTIATION; DRUG REPOSITIONING; DRUG SCREENING; DRUG TARGETING; HEALTH CARE QUALITY; HUMAN; IN VITRO STUDY; INTESTINE FLORA; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; BACTERIUM; CLASSIFICATION; COHORT ANALYSIS; DRUG EFFECT; GROWTH, DEVELOPMENT AND AGING; HIGH THROUGHPUT SCREENING; MICROBIAL VIABILITY; PRECLINICAL STUDY; REPRODUCIBILITY; SYMBIOSIS;

BACTERIA (MICROORGANISMS);

ANTI-BACTERIAL AGENTS; ANTIPSYCHOTIC AGENTS; BACTERIA; COHORT STUDIES; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, BACTERIAL; GASTROINTESTINAL MICROBIOME; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IN VITRO TECHNIQUES; MICROBIAL VIABILITY; REPRODUCIBILITY OF RESULTS; SYMBIOSIS;

EID: 85043332830     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature25979     Document Type: Article

References (40)

1. Khrstrm, C. T., Pariente, N. & Weiss, U. Intestinal microbiota in health and disease. Nature 535, 47 (2016).
2. Forslund, K. et al. Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota. Nature 528, 262-266 (2015).
3. Imhann, F. et al. Proton pump inhibitors affect the gut microbiome. Gut 65, 740-748 (2016).
4. Jackson, M. A. et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut 65, 749-756 (2016).
5. Rogers, M. A. & Aronoff, D. M. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin. Microbiol. Infect. 22, 171-179 (2016).
6. Flowers, S. A., Evans, S. J., Ward, K. M., McInnis, M. G. & Ellingrod, V. L. Interaction between atypical antipsychotics and the gut microbiome in a bipolar disease cohort. Pharmacotherapy 37, 261-267 (2017).
7. Falony, G. et al. Population-level analysis of gut microbiome variation. Science 352, 560-564 (2016).
8. Tramontano, M. et al. Nutritional preferences of the human gut bacteria reveal their metabolic idiosyncasies. Nat. Microbiol. https://doi.org/10.1038/s41564-018-0123-9 (2018).
9. Ejim, L. et al. Combinations of antibiotics and nonantibiotic drugs enhance antimicrobial efficacy. Nat. Chem. Biol. 7, 348-350 (2011).
10. Taber, H. W., Mueller, J. P., Miller, P. F. & Arrow, A. S. Bacterial uptake of aminoglycoside antibiotics. Microbiol. Rev. 51, 439-457 (1987).
11. Blaser, M. J. Antibiotic use and its consequences for the normal microbiome. Science 352, 544-545 (2016).
12. Rani, N., Sharma, A. & Singh, R. Imidazoles as promising scaffolds for antibacterial activity: A review. Mini Rev. Med. Chem. 13, 1812-1835 (2013).
13. Harbut, M. B. et al. Auranofin exerts broad-spectrum bactericidal activities by targeting thiol-redox homeostasis. Proc. Natl Acad. Sci. USA 112, 4453-4458 (2015).
14. Farha, M. A. et al. Antagonism screen for inhibitors of bacterial cell wall biogenesis uncovers an inhibitor of undecaprenyl diphosphate synthase. Proc. Natl Acad. Sci. USA 112, 11048-11053 (2015).
15. Pasolli, E., Truong, D. T., Malik, F., Waldron, L. & Segata, N. Machine learning meta-analysis of large metagenomic datasets: Tools and biological insights. PLOS Comput. Biol. 12, e1004977 (2016).
16. Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Bckhed, F. From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell 165, 1332-1345 (2016).
17. Arumugam, M. et al. Enterotypes of the human gut microbiome. Nature 473, 174-180 (2011).
18. Donaldson, G. P., Lee, S. M. & Mazmanian, S. K. Gut biogeography of the bacterial microbiota. Nat. Rev. Microbiol. 14, 20-32 (2016).
19. Hens, B., Brouwers, J., Corsetti, M. & Augustijns, P. Supersaturation and precipitation of posaconazole upon entry in the upper small intestine in humans. J. Pharm. Sci. 105, 2677-2684 (2016).
20. Bailey, C. J., Wilcock, C. & Scarpello, J. H. Metformin and the intestine. Diabetologia 51, 1552-1553 (2008).
21. Schloissnig, S. et al. Genomic variation landscape of the human gut microbiome. Nature 493, 45-50 (2013).
22. Kuhn, M., Letunic, I., Jensen, L. J. & Bork, P. The SIDER database of drugs and side effects. Nucleic Acids Res. 44, D1075-D1079 (2016).
23. Bodet, C. A., III, Jorgensen, J. H. & Drutz, D. J. Antibacterial activities of antineoplastic agents. Antimicrob. Agents Chemother. 28, 437-439 (1985).
24. Stringer, A. M., Gibson, R. J., Bowen, J. M. & Keefe, D. M. Chemotherapyinduced modifications to gastrointestinal microflora: evidence and implications of change. Curr. Drug Metab. 10, 79-83 (2009).
25. Sharma, S. & Singh, A. Phenothiazines as anti-tubercular agents: Mechanistic insights and clinical implications. Expert Opin. Investig. Drugs 20, 1665-1676 (2011).
26. Morgan, A. P. et al. The antipsychotic olanzapine interacts with the gut microbiome to cause weight gain in mouse. PLoS One 9, e115225 (2014).
27. Li, X. Z., Plsiat, P. & Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 28, 337-418 (2015).
28. Nagy, E., Urbn, E., Nord, C. E. & ESCMID Study Group on Antimicrobial Resistance in Anaerobic Bacteria Antimicrobial susceptibility of Bacteroides fragilis group isolates in Europe: 20 years of experience. Clin. Microbiol. Infect. 17, 371-379 (2011).
29. Cacace, E., Kritikos, G. & Typas, A. Chemical genetics in drug discovery. Curr. Op. Syst. Biol. 4, 35-42 (2017).
30. Morita, Y. et al. NorM, a putative multidrug efflux protein, of Vibrio parahaemolyticus and its homolog in Escherichia coli. Antimicrob. Agents Chemother. 42, 1778-1782 (1998).
31. Sulavik, M. C. et al. Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes. Antimicrob. Agents Chemother. 45, 1126-1136 (2001).
32. Nichols, R. J. et al. Phenotypic landscape of a bacterial cell. Cell 144, 143-156 (2011).
33. Nasie, I., Steiner-Mordoch, S. & Schuldiner, S. New substrates on the block: clinically relevant resistances for EmrE and homologues. J. Bacteriol. 194, 6766-6770 (2012).
34. Ariza, R. R., Li, Z., Ringstad, N. & Demple, B. Activation of multiple antibiotic resistance and binding of stress-inducible promoters by Escherichia coli Rob protein. J. Bacteriol. 177, 1655-1661 (1995).
35. Gustafsson, C. & Persson, B. C. Identification of the rrmA gene encoding the 23S rRNA m1G745 methyltransferase in Escherichia coli and characterization of an m1G745-deficient mutant. J. Bacteriol. 180, 359-365 (1998).
36. Roldn, M. D., Prez-Reinado, E., Castillo, F. & Moreno-Vivin, C. Reduction of polynitroaromatic compounds: The bacterial nitroreductases. FEMS Microbiol. Rev. 32, 474-500 (2008).
37. Matthews, D. A. et al. Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate. Science 197, 452-455 (1977).
38. Clemente, J. C. et al. The microbiome of uncontacted Amerindians. Sci. Adv. 1, e1500183 (2015).
39. Spanogiannopoulos, P., Bess, E. N., Carmody, R. N. & Turnbaugh, P. J. The microbial pharmacists within us: A metagenomic view of xenobiotic metabolism. Nat. Rev. Microbiol. 14, 273-287 (2016).
40. Kritikos, G. et al. A tool named Iris for versatile high-throughput phenotyping in microorganisms. Nat. Microbiol. 2, 17014 (2017).